Table 1.
Lifestyle-related and preoperative clinical factors.
| B (n = 32) | C (n = 93) | NBNC (n = 76) | P value | |
|---|---|---|---|---|
| Age (years) | 61.1 ± 13.6 | 67.2 ± 6.6 | 71.0 ± 9.2 | <0.001 |
| Gender (male/female) | 23/9 | 70/23 | 67/9 | 0.058 |
| Obesity | 3 (9.4%) | 17 (18.3%) | 15 (19.7%) | 0.412 |
| Hypertension | 6 (18.8%) | 26 (28.0%) | 36 (47.4%) | 0.004 |
| DM | 5 (12.0%) | 20 (21.5%) | 27 (35.5%) | 0.041 |
| Cigarette smoking | 19 (59.4%) | 55 (59.1%) | 47 (61.8%) | 0.933 |
| Ethanol ≧ 20 g | 5 (15.6%) | 38 (40.9%) | 46 (60.5%) | <0.001 |
| Albumin (g/dL) | 3.6 (2.3–4.5) | 3.7 (2.8–4.5) | 3.8 (2.5–5.0) | 0.104 |
| Total bilirubin (mg/dL) | 0.5 (0.2–1.2) | 0.5 (0.2–1.4) | 0.5 (0.2–1.3) | 0.873 |
| Platelet count (×104/mm3) | 14.0 (4.3–48.9) | 16.1 (4.4–51.0) | 19.2 (6.7–51.6) | 0.020 |
| NLR | 2.21 (0.79–4.90) | 1.92 (0.52–14.16) | 2.16 (0.67–12.80) | 0.271 |
| PT (%) | 82.9 (64.3–105.0) | 90.0 (63.4–122.7) | 95.4 (54.8–131.4) | 0.002 |
| ICG R15 (%) | 12.7 (4.4–19.7) | 14.0 (2.8–42.3) | 10.9 (1.6–36.7) | 0.027 |
| Child-Pugh B/C | 2 (6.3%) | 5 (5.4%) | 6 (7.9%) | 0.802 |
| AFP (ng/mL) | 110.0 (1–605100) | 14.0 (2–11675) | 6.0 (1–48157) | <0.001 |
| DCP (mAU/mL) | 267.0 (10–174400) | 148.0 (10–23950) | 87.0 (11–85330) | 0.653 |
| Multiple tumors | 10 (31.3%) | 25 (26.9%) | 22 (28.9%) | 0.885 |
| Tumor size (cm) | 5.2 (1.0–20.0) | 3.0 (0.7–11.0) | 4.5 (1.0–17.0) | 0.001 |
| ≧10 cm | 7 (21.9%) | 2 (2.2%) | 14 (18.4%) | 0.001 |
| BCLC stage B/C | 8 (25.0%) | 16 (17.2%) | 18 (23.7%) | 0.484 |
| Beyond Milan criteria | 15 (46.9%) | 26 (28.0%) | 38 (50.0%) | 0.009 |
| Preoperative TACE | 17 (53.1%) | 60 (64.5%) | 42 (55.3%) | 0.356 |
DM: diabetes mellitus; NLR: neutrophil-to-lymphocyte ratio; PT: prothrombin time; ICG R15: indocyanine green retention rate at 15 minutes; AFP: serum α-fetoprotein; DCP: des-r-carboxyprothrombin; BCLC: Barcelona Clinic Liver Cancer; TACE: transcatheter arterial chemoembolization.